His main research concerns Internal medicine, Oncology, Glioma, Surgery and Temozolomide. Within one scientific family, David A. Reardon focuses on topics pertaining to Gastroenterology under Internal medicine, and may sometimes address concerns connected to Regimen and Gliosarcoma. His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Cilengitide, Nivolumab, Radiation therapy and Pharmacology.
His Glioma research includes elements of Salvage therapy, Central nervous system disease and Pathology. His work deals with themes such as Adverse effect and Clinical trial, which intersect with Surgery. His research integrates issues of Immunology, O6-Benzylguanine, Chemoradiotherapy and Dacarbazine in his study of Temozolomide.
His primary areas of study are Internal medicine, Oncology, Bevacizumab, Glioma and Temozolomide. His studies in Internal medicine integrate themes in fields like Surgery and Glioblastoma. His study in Oncology is interdisciplinary in nature, drawing from both Cancer, Chemotherapy, Clinical endpoint, Recurrent glioblastoma and Pharmacology.
The study incorporates disciplines such as Angiogenesis, Progression-free survival, Irinotecan, Vascular endothelial growth factor and Nivolumab in addition to Bevacizumab. His Glioma study combines topics from a wide range of disciplines, such as Pharmacokinetics, Toxicity and Pathology. The various areas that David A. Reardon examines in his Temozolomide study include Adverse effect and Dacarbazine.
His primary scientific interests are in Internal medicine, Oncology, Glioblastoma, Cancer research and Bevacizumab. In most of his Internal medicine studies, his work intersects topics such as Glioma. His Glioma study combines topics in areas such as Mutant and Pathology.
He has researched Oncology in several fields, including Cancer, Survival rate, Temozolomide, Nivolumab and Recurrent glioblastoma. As part of one scientific family, David A. Reardon deals mainly with the area of Glioblastoma, narrowing it down to issues related to the Newly diagnosed, and often Radiation therapy. The Cancer research study combines topics in areas such as Receptor and Immune system, Immunotherapy.
David A. Reardon spends much of his time researching Internal medicine, Oncology, Cancer research, Clinical trial and Bevacizumab. His study brings together the fields of Glioma and Internal medicine. His research in Oncology intersects with topics in Survival rate, Cancer and Glioblastoma, Temozolomide.
His Cancer research research incorporates elements of T cell, Immune system, Immunotherapy and PI3K/AKT/mTOR pathway. His work carried out in the field of Clinical trial brings together such families of science as Isocitrate dehydrogenase, Neurologic Oncology, Response assessment and Intensive care medicine. His Bevacizumab study incorporates themes from Pembrolizumab, Phases of clinical research, Vascular endothelial growth factor, Combination therapy and Biomarker.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
IDH1 and IDH2 Mutations in Gliomas
Hai Yan;D. Williams Parsons;Genglin Jin;Roger McLendon.
The New England Journal of Medicine (2009)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello.
Journal of Clinical Oncology (2007)
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell.
Clinical Cancer Research (2007)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge.
Lancet Oncology (2014)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid.
The New England Journal of Medicine (2018)
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell.
Journal of Clinical Oncology (2004)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape.
Journal of Clinical Oncology (2010)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin;Annabelle J. Anandappa;Jing Sun;Itay Tirosh.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F. Cloughesy;Aaron Y. Mochizuki;Joey R. Orpilla;Willy Hugo.
Nature Medicine (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: